GBT - Earnings call transcript Q2 2021 | Global Blood Therapeutics Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to Global Blood Therapeutics Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the prepared remarks. [Operator Instructions].

As a reminder, this conference is being recorded. to call like Immergut. to now would turn over the Steven I go sir. Please ahead,

Steven Immergut

and conference of Thank the to and I'm welcome you, GBT's of Head results provide business Communications the Steven to Immergut, company's Relations. call for second and quarter XXXX Investor a update. financial discuss to

Financial Kim provide Ted XX, catalyst our are quarter; our on progress future. Oxbryta results; the financial Earlier Dr. quarter of second the pipeline. will Joining Love, Head then a and or Chief this President update me call DJ, afternoon, give ended on second review and launch; for give Commercial June an GBT’s our Farrow, we Officer, our closing David Vice release Johnson, and Officer, our the Chief Jeff progress Smith-Whitley, issued Ted announcing a the GBT's financial President an Dr. on CEO, will results our who R&D, will will press our the on discuss update few XXXX. in for Executive remarks will

at the recent our quarterly contained Investors from SEC company are would release. to well to in releases and Information our filings, factors can Before may I materially differ our press not SEC or Form that site report in by forward-looking actual expressed facts our of on implied be statements are call that like filings including, limited XX-Q on such most uncertainties. begin, remind are of historical certain statements you be that Web Copies forward-looking results today's to statements we risks not we page and make subject that gbt.com. this as but could concerning from those to, obtained press as

over the Forward-looking update the on to any on only I'll events as place to should other change any you call statements. not statements of beliefs With Ted. such than and they our call obligation simply passage undue as cause of reliance this we made, time are required to may Future and by are made the forward-looking time that, disclaim law. statements turn or

Ted Love

good to everyone. GBT trials made on P-selectin up for by the and long-term our of GBT highlight SCD around itself transform of just quarter, Steven, the inhibitor robust a sickle in solid regulatory lives In success fundamentals we afternoon, the the disease cell the care you, think two recently for to vaso-occlusive and want inclacumab, and pipeline. mission for of of crisis setting improve remains Thank we launch and The clinical class. our strategies world. strong Oxbryta X the Phase advancing patients be is progress our U.S. initiation in announced I that pivotal best will that second

in bring innovation on of data year. by for sickle X potential the to our these GBTXXX initiated with to very and proof goal disease. excited We delivering of trial track XXX patients. We're cell the by of developments Phase remain further We also our our cell sickle of therapeutic concept end

prescriptions new in quarter, onset range COVID-XX seen the to we've the since We XXX the Oxbryta. with turning pandemic. approximately consistent Now delivered the of

we it. not While we this satisfied result, anticipated are with

encouraged are factors. we forward, key several Looking by

key of increase quarter. expectations. revenue continues Oxbryta our number each This delivering a net the patients on First, quarter to is of second driver

Oxbryta. who prescribers of sickle Oxbryta key setting values. satisfaction levels real-world a third, the overall as and improvement therapy potential patients in of lab status and And clinical disease, demonstrates evidence demonstrates experience growing body validate tried of have continues latest cell market to research in our of of for high Second, foundational the patients real-world among a role

a for the groundbreaking feedback and direct-to-consumer addition, exciting year, In including we have several educational initiatives of are positive our marketing and programs, on advertising we planned receiving the launched recently began campaign. environment second rates quarter, in geographies. patients COVID-XX and for as overall In restrictions improvement of vaccination lift sickle increased cell to the signs show to began gradual the rest many

For towards sickle vaccine cell the is patients, improving. sentiment

the rate still of lowest Americans vaccination. Black have However,

failure often, experienced is are death. told Patients we increase in is an by of disease fact disease doing it a of longstanding continues of along pain our a GBT aren't inequalities cell when all if patients. Delta begun more recently, well the pain, cell often return variant are disease sickle sickle crises. the they multi-organ to be guidelines. know, a has characterized As to and the COVID-XX as and a and drive Too they headwind experiencing with cases in health for restrictive COVID-XX community, premature

know create change, these a to suffering standing not deaths to opportunity due we patients is and premature meaningful are This So are still. we hemolysis.

needs disease. we Equity on community We healthcare are treating with creating educate of our sickle systemic We urgency and to gaps those of Health on a This prominent that impact issues living other of prioritize with sense along with focused leaders sickle with among greater the are disease. SCD, members to disease community. the HCPs continuing is a on include, in actions the care. people group cell significant care access urgent the few formed to other of A highlights cell of actions advocacy patients Council with this working

improve in in co-host Therapeutics September, for Annual organizations approximately to Conference and in Association community-based Sickle future addition, ACCEL discuss with leaders programs Cell we the together for Disease $XXX,XXX Disease And America, bringing high Sickle the trends program latest cell to SCD. to funding of XXth sickle Cell our community that in will the the advances in sustainable provided patients. quality this access In year institutions grant care

including I these for designed over equity them patients Oxbryta. review sickle efforts second disease, and quarter Jeff improve With results. are cell helping health with innovative to like more will All call medicines the access to of turn our to that,

Jeff Farrow

first first on inventory patient was the flat, base. relatively of of decrease reflects the in approximately in offset of a quarter of Total of million mix XX% increased, flat XX.X from increase from increase second patients. new second at the sequential a quarter from XX%. revenue driven to an of increased levels Ted. This The year-over-year. Days insurance second was by number net deductibles the growth an hand absolute support or XX% you, million increase was reflecting by following Gross XXXX, first was patient in out-of-pocket net of and quarter. the growing Oxbryta, XX.X revenue commercial continued On the XXXB although sales inventory Oxbryta existing in from the including the net Thank copay Oxbryta sales sequential quarter quarter. basis, for on of patients in by the demand the quarter reset

cell closely COVID We particularly that driven being variant, are patients case disease. in tracking geographies most new rates Delta by the with sickle include the

we want expectations. headwind, ongoing the to specific provide Given

the quarter, inventory to the prescriptions reflects For dynamics, third expect major and COVID revenue net as in third uncertainty million, anticipates two as of million XX holidays gross to we of the well quarter. and XX around flat new relatively current the which impact

Looking to the corresponding improvement improves, pandemic anticipate if that revenue will prescriptions continue forward, gradually in growth. and we we new see a

costs to the in a Oxbryta with expense to as and Oxbryta to the sales low R&D quarter was for XXXX of of with the XXXX FDA consistent was gross of year-over-year. were majority to due prior years was approval, with for compared on were expenses. of period quarter primarily R&D margin compared in incurred sales the the of as XXX,XXX expense. preclinical thus quarter XX R&D XX along Cost of clinical and for in second basis as quarter Cost XXX,XXX costs The increase million recorded advancement both for second Now related related the our in second programs, sales programs. the million second and turning was inclacumab same manufacturing XXXX. expense to

a for million sequential We X R&D inclacumab, third continue begin expense quarter trigger in two we in a milestone increase by the enrollment which will Phase the to as payment anticipate in GBT. $X studies

including period We period Oxbryta. million quarter increase also with by the compared activities. anticipate share compared million million $X.XX the of net We loss expense diluted in for consulting share period for program, for the and in third share the for studies was same for services second measured advancement the same primarily incremental expansion the professional in the sponsored XXXX. Net and compared the in increased second fourth the our investigator Basic million rollout for quarter increase XX an XX driven the in the materials, second expected of increase inclacumab other including the XXXX quarters, studies. expense driven to multiple Oxbryta of was loss other XXXX. with SG&A same with advertising, $X.XX GBTXXX per pipeline-related in DTC stock fourth and quarter was per stepwise initiation XX and and of expect employee-related SG&A efforts commercialization the in associated non-cash per SG&A for by to XXXX. was a costs, The into XX our due compensation our quarter Europe

with to at positioned now with million cash, to We And marketable with December will be the continue a compared turn equivalents over XXX of DJ. XXXX. strong call quarter million at with securities cash balance well and that, XXX sheet, end XX, I

David Johnson

everyone. and afternoon, and progress Thank excited our initiatives. launch about delivered and of are Jeff, We you, quarter another good solid upcoming recent

Oxbryta, progress. give patient access will three done coverage, around are adoption; which of an payer will As that I prior informs prescriptions into Oxbryta. insight which are the for the I've and captures metrics speaks in demand; update number to Oxbryta, environment These our the new provide metrics which for quarters, in underlying we key further you prescribing providers healthcare making progress the

prescriptions. have during with the There quarter, range new were for the new prescriptions of we since pandemic. onset the consistent the First, approximately XXX seen Oxbryta

overall the a in-person deeper time, potential pre-pandemic with prescription visits new existing from consistent we improved several believe levels growth, prescribers. particularly of visits, significant and for remained below past Oxbryta in that there's penetration in-person somewhat appears in it with While QX, inclusive and quarters. telemedicine, patient Over

top our existing of among prescribers their to for prescribers, an have ample patient example, Oxbryta penetration penetrated are compares This into average around XX who opportunity growth. demonstrating our For we population. XX%, XX%

of result, to interactions. a the of our of growing team our XX% we providers, is including the In number with reached in-person priority quarter, engage these continuing top targets. second the As healthcare

patients on groundbreaking awareness patients Oxbryta.com and to The on commercial and adoption have ask a available first in disease, cell the impact As of patients’ positive will who we kind features their social Oxbryta at sickle It with a providers. campaign end direct-to-consumer Oxbryta engage marketing and messages an empowering a commercial families. Ted patients is highlights TV to new centerpiece as that action call and will actual July. for it media. prompt name. healthcare we This Oxbryta believe our help be targeted that The and also on is launched for and the mentioned, serves its of commercial by

market also closely White is plan a be. to are influence our from lower factors We received that increase Black from May-June February-March rate research than showed at to dosed Hispanic, XX% Kaiser as those cell, the a CDC With This soon XXX COVID-XX the or XX% Foundation highlight showed sickle and respect data from is that XX% patients significant Family already and vaccinations, XX% the with prescriptions. timeframe, population possible. monitoring around to dose additional to which in as Specific and populations. Asian planning the vaccinated

For around safety well data. as due longer remains effects fears waiting the as hesitancy remaining side for vaccine to XX%, term prominent and

initiatives. other to Turning

electronically prescription help and with We to for on providers support are which stay forms our stable and and authorization platform an we speed patients are during conversions, providers. and well to for rate the compliance healthcare now efficient To adherence, the partnering provides prior CoverMyMeds, will focused integrated healthcare believe persistence, quarter. and therapy. submit range start within easier to providing new the this improve of be of on Oxbryta payers. which was We includes both more analogs

number of on therapy patients restarting are significant discontinued a that addition, In Oxbryta.

to and our received that include are hub, Source. on support started accessing gbtsource.com our have feedback patient touch improvement. XXX% and initiatives We a launched our positive guides new patient Web brochures, site for patients they transition further adherence initiatives our model high getting These to kits, and will optimistic recently to lead GBT

the Our form of the strong to of fundamentals providers market or continues to support prescribe Nearly research others. are symptom majority in all aware of likely Oxbryta, some And Oxbryta. improvement it already patients also and to report plan they recommend experienced who healthcare have to of for are they the it that future.

my Looking second health, suggesting and see the range at and to continue long-term me characteristics are as baseline hemoglobin to polymerization addressing of metric, use, we leads which such that VOC importance Oxbryta of penetration. broad a increasingly prescribers healthcare burden, recognizing provider

lower the month, quarter, of providers levels. first interactions but quarter, healthcare percentage incrementally total each with in-person pre-pandemic with compared still the substantially During increasing steady the interactions remained to than

In the breakdown launch. added by we in-person around addition, prescribers since a around we total which to written trajectory we writers, hospitals being for see XXX prescriptions in cautious and the of quarter, the at X,XXX When to positive look backdrop, and about institutions non-specialists, of bringing Against visits. remain we prescribers our both continue long-term this trend believe the specialists is launch.

Turning to we coverage prescriptions to patients contributed strong therapy. having the lives payer XX% has coverage. achieved In in converting more to than in starting coverage efficiency covered XXXX, improved with new This broad United access States. of

partners. for pharma patients copay the card pleased work We program half in XXXX, our access after of through have been to of specially streamlining that first utilization expanded see our

helping ever have payer of result, now a And on in are Having a we majority of patients to been prescribe less. patients for Oxbryta. coverage than before. patients Medicaid, types $XX it and large copay to we achieved easier a physicians almost across receive focused XXX% our have all As or more making

plan get a improves are and on adoption. on patients ability Texas, strategic Medicaid must win is to Oxbryta good drive formulary, success confidence the all In have of important in summary, August speaks open and their in our progress This follow. Oxbryta. has provides added to to which common that our for growing This X. For to just Michigan to as making example, we similar focus managed access initiatives to label therapy our an to Oxbryta

the field We the continue more are over to Kim get eager in turn and to call And access and on Oxbryta. talk receive feedback to that, with in excellent will our the pipeline. expand to exciting patients I about developments now

Kim Smith-Whitley

my pick in this as made you, their and up clinician Ted good disease. a earlier afternoon, result. It's perspective as more known experience well access years a a point want had outcomes sickle DJ, provide high than I XX care to to health suffered with and cell haven't patients Thank everyone. that on and of reliable quality have

to We chronic also know death. have cell and patients which hemolysis, organ and eventually anemia long-term damage that sickle lead

disease. and to the the knowledge We tools have this transform treatment of

real very remain. However, gaps

of but I of tell As authors the not Engineering am one published in the year and Sciences, like cell sickle last profound, on fueled the are that needs of is National you cell Oxbryta. by Plan optimistic. insurmountable. disease Strategic of disease National good part the Medicine, Academies I at can the sickle care There momentum, in innovations

educating deeper patients PROSPECT. to was X PROSPECT, we sometime anticipate from and an registries, gather cell and professionals cell at the will hemoglobin with Initial of and is XX% safety will to a RETRO meeting addition were Oxbryta We period will the The patients In XX retrospective presenting meeting disease to adolescents approximately patients and two quarter measures up on in cause, evidence. five in and up per outcome deciliter. begin Oxbryta more resource the registry treating of results pre collecting health capture initiation to that presented sickle Oxbryta of this A first pre-enrolling year in outcomes full December registry PROSPECT and pre efficacy sites therapy. the sickle post up on important the of X will long-term records be publish study. drivers U.S. in other were at in multicenter of in to XXXX. took real-world presented line real-world provide XXX key believe support data the year Oxbryta’s data, of past enable RETRO the approximately XXX results RETRO is at underlying of adults and patients. registry disease step that of registry, the very Phase from additional initiation will based U.S. and from clinical real-world sites medical prospective that greater one HOPE These we large its studies health a a initiation our increase for of evidence measures, use gram one capture post laboratory utilization We in understanding measures results results from to one XX updated June. spanning anticipate EHA at therapy. in XX XXXX. and years the the ASH RETRO a same with achieving than RETRO the That's is

the first real-world additional provider We the data ASCO, at meeting, healthcare the continue EHA community. generated Dr. Anderson evidence Alan to he also At presented update see presented an by to X corresponding increased in hemolysis levels patients showing by grams markers hemoglobin that treated of an with the exceeding of average steady. per results Oxbryta, HOPE overall XX in deciliter improvement with

by option. our dosing the practice This progress, meaningful very sickle quarterly One We named to Turning is two to has programs. as and [ph]. reduce our aligned collectively quarterly VOC reduction track schedule over current We're improvement of XX-week for studies be a monthly pipeline. initiated to cell Inclacumab, treatment we with potential and disease of period. typical aims on lead X with inhibitor for VOCs with patients dosed P-selectin our would to a check-ins. opposed encouraged THRIVE remain a the Phase be

to following Subject for readmission submissions independent plan tragically which an trials, in to to hospitalization, of XX-day The these VOC patients. reduce initial indications. regulatory VOC two around occurs study the second XX% separate file aims we results of

with PK/PD to have inhibitor, safety, a For over expanded healthy and XX-week GBTXXX, and completed treating the we volunteer into hemoglobin period. tolerability our people XXX disease sickle polymerization of assess next a study generation cell

once hemoglobin in functional great Outside to eliminate meeting and the treatment potential of plan programs. long-term disease continue we plus be December. believe data our level what's advance efficacy two in best-in-class to to potential pipeline, the cell present complementary have providing X our with we And therapy. data, at robust the lead is in-house really ASH and our could we to patients XXX options. cure preclinical a a to If studies pill. sickle this preclinical exciting a we Phase XX% all for similar symptoms multiple in-licensed treatment With shows is that believe data and daily the organ has damage, of the Our programs, modification these transform of range, from

we seeking These States, a XX. to applications pediatric other the Turning NDA separate our regulatory to expand our for now aged for formulation. include R&D-related include label the label new to children X a the United In initiatives. a submitted supplemental and Oxbryta expanded to NDA

sNDA data EHA study, presented detected. the the XX HOPE from in children data adverse an new HOPE-KIDS safety which included and Our meeting Phase The signals were oral consistent at X Xa with June. in no presentation the study, was from was

additional Oxbryta Oxbryta experience protocol We clinician early to are old. launched to patients. in children XXX the up provides building Based on strong upsizing to aged January, in a through the to with XX access from which we protocol interest, XX years X U.S. pediatric are

As suggest of the accelerator the eager to and perspective, proactively. this to the high. myself a could the From healthcare blood think more earlier, the course particularly important age will believe we mitigate are an I treat complications. expansion threatening potential is modify And if alleviate young providers among adoption Similar disease as that another as pediatric provider be and many adherence and to the with great providers. I adoption serious destruction, pediatric has that sickling hydroxyurea, cell to cell opportunity option, red in be could treatment have practitioners, group of Analog life is patients likely address four included, to potential robust we need. future disease adult which it vital this years said old it sickle of children Oxbryta

over building to to Germany, and Oxbryta Oxbryta review make we America. us more together, And will approval, continue countries, remain also are explore In it we expansion for patients on limited of East medicine to All intended potential to Ted. schedule and marketing with available Kingdom. approved and the the geographies, make of to such working than could other promising Turning patients to available the opportunity continue a as we that, Latin resource of with label We half reach the I'll our believe plans therapies give world against designation to strategies in around XXX,XXX of EMA’s are India. momentum advance Outside years. the next cell France, Africa our to be sickle and to United progress early the And the we our we turn we in access first Europe. several which in this goal, application, Middle in are as in with in over innovative received bring global Europe, back XXXX.

Ted Love

Kim. success. leadership opportunity well Thank we've reach to excited development and cell really sickle positioned GBT In patients. you, our more today its I'm disease for continues closing, the in about outlined long-term is and

We important of months. a catalysts next series XX have anticipated over the

among as will expect potential in as children U.S. be with example, patients four our of of the years young outlined, For and augmented age. Europe the old, half first as approvals momentum years in XX in over two Kim in XXXX; we

later pipeline robust look with and as inclacumab to best-in-class move We year. potential to reporting a Our early GBTXXX option. forward this results we're is And excited on advancing. forward

stronger community to to GBT’s lives we improve commitment our forward, As ever, patients. we supporting is the strive the of cell sickle than go as

cell in our passion well into the and sickle effort. questions. team this to thank And call With of Our their a is I dedication disease for for goal is managed we'd to employees transforming which like condition. Operator? want unified that, achieving to essential open

Operator

Thank you. [Operator Instructions].

Breidenbach Our from Oppenheimer. is Mark proceed. Please with question first

Mark Breidenbach

the on trial the trials. under of sNDA? your the redundant question trials and you're for served sustained Kim. and like was you Thinking inclacumab at NDA the I inclacumab, need both patients other. these Can be what a expansions. Congrats just the who be NDA guys. the versus degree on kind for bit understand of little These the I would hoping is To the Hi, why help are the there's pediatric us And my and could and label sNDA for thanks might sort questions. both second taking of sizing applications quarter for the directed by I patients patients, back expectations believe XXX And sounds of be we relative of was the that tell think an the indication those to only for about two XXX for inclacumab, efficacy assumptions? into maybe about and you XXX antibodies? powering should it questions. for taking us in of sizes differences anything just one targeting trial the reading Thanks the larger as

Ted Love

And on add Kim, to stab feel I'll Mark. questions few take free Thanks, free feel the add at sNDA. a But and on. to

good of The that a first voice. there's Mark, clinical update because So, is the information actually sNDA all, for label. to approved your the to is question. hear an Thanks your reason

that's new in to its NDA has a new own. be So formulation The sNDA. on

overpower the tend But and out we So trial under The stress that's we the regard a we powered. significant new We studies. the generally studies formulation. to details size, And to give the formulation of that in rather how pediatric anything studies you're One if our With do sNDA. don't an power why them. we than tend is of power our is NDA for have our right. are to clinical. have for new NDA the

of to was just a be little believe bit They the north is study though. Our study subjects. designed dropouts did have I inclacumab XXX larger.

did XXX they may believe I study But I at patients. our the numbers. I around looking don't be patients. enroll you than numbers is that. the more So exact final remember believe being XXX

be study is look to at for which is Our powered the a we readmission, say, again, XX%. we we're to talk rate. in expect is endpoint around sense. bottom a hospital readmission in to around powered rate XX% hospital But the control tend powered don't reduction well much actually different that we a about even, heavily let's line But XX% too be details. And

that free like. you’d to So, add feel Kim, to if

Kim Smith-Whitley

Ted. you. was No, great. That Thank

Mark Breidenbach

Thank you.

Operator

with Alethia Cantor. Please proceed. question next Our is from Young

Alethia Young

vaccinations potential just you dynamics quarter. light wanted third something on the confident taking it's flat. you probably question one all -- And I for DTC variant of then I can is have in that granularity like populations, be my of of guess like you you makes campaign, in talked to upfront? what’s on kind and I Thanks like Delta this from more sounds just new the see But it’s how to gleaned I and fourth had the And of and that versus if just you. now know just question underserved what my the other are scripts? it achieve nice I now you get kind inflection in going Thank to maybe do initially some that is quarter could want quarter. it about.

Ted Love

you're Right. Thank DJ, But you, infection, may to hear Alethia. Good to that right. more specifically. want talk you regard to an say with your voice. would I

we kind of heading wrong you been the with Delta are we've have in to been restrictions we that We point hoping in the what support. in some environment. of have the can with wrong we're a going the were organization as liberalize diminish. is can't continue push we Unfortunately, that our well as COVID variant, lot so as But on patient the the we to push direction, where our of and direction infections going materials, patients. both We control profoundly control our truth on to things out the can all states doing, educational greatly

feel everything about The that time the because be to excited get very add commercials are more we initially But to DJ, about free has reason DTC. things of approved. please the some takes you're is And do do We some FDA it doing, that we particularly that approved. couldn't that the to DTC.

David Johnson

add always started take Web we our to with more bit time Yes. had. plan. Thanks, the to well, They've does get new part before We very FDA. always the campaign a included market educate media It Ted. take was started does social commercial And the on those. thanks, something and holistic produce of approach robust And a we it advertising. But Alethia. that well. digital Oxbryta that had that to That's wanted through to DTC campaign And we been exactly commercial. in with that as is that campaign updated we've then right. a been as sites time it

everything's up And us of kind now. So lined for Ted’s right.

headwind unique doing not kind for what unique campaigns. on it think efficiently. and patients physicians yourself to a we're We're but lot GBT I activating this the instruct forward. this the it's help of a a lot CoverMyMeds lot. industry, course, And to long-term pandemic, we're process, going that's to up success is to We're of set doing directly. more now, you're adherence with doing educating And patients the doing about

of that us all help we for that future fully So out expect. we things these think growth

Alethia Young

Okay, great. Thank you.

Operator

Our next Leerink. proceed. Andrew is SVB from Please with question Berens

Andrew Berens

Hi. Thanks.

strong Let the my add guys. me congratulations sales quarter, also on

Ted Love

you. Thank

Andrew Berens

Sure. from hydroxyurea, patients irrespective getting drug anecdotal on using We've the physicians hemoglobin that of been fail level. some the they're feedback that

therapy So increase what getting gain drug increase it seeing wondering return they it percentage reasons you did are it? Adakveo? Oxbryta the are the know patients other getting patients rate? And lastly, that prepared then you you of during if what Are than missed getting to for the hemoglobin. have then after was to percentage of I any persistence also patients might stopping I comments. And also in But update

Ted Love

are than of some there to on start those. other to say reasons DJ Oxbryta your will patients of to yes, physicians add one that But want would for I definitely hemoglobin. questions,

do leg Oxbryta difficult from label a underlying is For The disease to to the have can some findings been have the relatively fundamentally heal. and have your of indication, encouraging drug very have along anecdotally, there example, base patients because is advancing, treat but hemoglobin doesn't I that to for know, intended actually hemoglobin anemia. are higher that. that including your prevent ulcers what

therapy know for to going to their children you I this being indicated probably like do in health anecdotally, with things more well, common but future, very hemoglobin, say, but know from to really go would begin young, doing maintain drop prevent before one which it term. to is future they're higher DJ? So in them of unlikely they we see theory, to a probably and they're the are hemoglobin relatively ours we continue the we will dropping. patients drop, in well. the of long even when to But are That's now, want want to treat reasons that also where

David Johnson

additional of Yes, couple just a comments.

start a in kind of sickle a it treatment actually which disease, on devastating are our of disease not, our believe naïve. such amazing. never treatment, So patients or They've lot Oxbryta is cell in been

been as we our Interestingly, as patients hydroxyurea our little alone. would are little in get Adakveo tolerate have but or a And But literally it our treatment well been on couldn't that as are have on combination all. Oxbryta half of therapies failed at also as any support, that patients and hydroxyurea previous under regimen. So that a over patients very that well. half patients data a includes that on commonly of actually not means

other with QX will persistency has been low talked what on that low And of say in quarter-to-quarter, up go that we double are consistent more at. as look about newer Adakveo. the has more as teens, digits to that expect we combination rate, And over so the within analogs time but fluctuates products. well rate get it we overall and not approximately a with range adherence experience I that people with that quarters and is fluctuated. our

a previous and that So seen ultimately have a to restarts, nothing about trend of to think you been restart we I as discontinue happen. quarters, report That's asked patients about restarts continue We've there. said phenomenon. in QX in continue bit then and that well. really And nice XX% therapy little

Andrew Berens

I Thanks Okay. color. the it. for Congrats appreciate again.

David Johnson

Thank you.

Operator

is Please question Capital Our from Piros proceed. with next Partners. ROTH Elemer

Elemer Piros

that team drugs? two from to the the since of the Yes. treated that between the what with Good patients you Adakveo we ask an estimation observed is have afternoon, Do every quarter number of discrepancy everyone. beaten What I'd we lunch? have like is

Ted Love

estimate dose. a bit patients Elemer. hard to good access little began for get question. a have a because because actually we don't Novartis’ obviously, us a to It's it's complicated, they little It's Adakveo, And when bit on Hi, data. also loading

So two doses the frontend. there on are

us a accurately. it's hard to So little estimate bit for

access get As you that drugs and both therapy. do know, this I very to cutting-edge personally am excited patients very well

But on. think their and our launches as not a numbers I of lot I we So compared put well numbers think is COVID, something their attention Certainly to looking going we're well. well. doing that are at

Elemer Piros

you different How that that Okay. are also countries. approved regard? compare XX in They do in Ted, they state,

Ted Love

one approved country. in We’re

So it's easy a comparison. pretty

an States, I the that the of a We in magnitude a on in America filed has working There's and are, distributorship United biggest already and significant truth as we've know, the Latin company GCC however, markets and and a infrastructure not Europe, is, Europe. are we're you market the of The Novartis. have we think there relationship there. already,

may are be the XX not around but of significantly, either in filed size market. towards end, application and the So the our or particularly increasing already in be numbers will markets moving the we likely

Elemer Piros

one beat you maybe, help out one And here. last still country with you versus question is Jeff, if them XX. And me could

Yet, fewer you is to are patients So you revenue it reconcilable Is or in the this drug of previous much patients it building and/or or existing appears by stack the had quarters. have the two than the the discontinuation that higher. in is rates declining? quarter, three adherence new fact improving a that

Jeff Farrow

great there. Elemer. the point base growing from of a the those that over It's the of continues, as come build a and launch bulk revenues of And to question, you patients. patients the that's highlighted bulk the Yes, the It middle time. ultimately is that to prescriptions really continue

of that where that a we that's benefit or in had growth Patients in maybe come two seeing quarter. only we're initiated get so the second we where lot And bottles three bottles, QX the of one from.

how that typically that's runs. So

Elemer Piros

much. Thank so Okay. you

Operator

with from Please Ritu Baral Cowen is Our question and proceed. Company. next

Ritu Baral

the further higher wanted why Phase you than patient was ask response those Good first restart? was driven afternoon, HOPE that to able that been the restarts. Thanks one I it dataset, follow to patient Anderson these hemoglobin And down they the a generated the the And data. drill my patients motivation on place? there? to hemoglobin up have may taking for about DJ, for have X was them about What increases quit EHA the what that increased profile questions. guys. the in little

Ted Love

why data. Alan's up DJ, on follow you can maybe, Kim, don't start then and So, you

David Johnson

Sure. Great question on the restart.

So we Oxbryta. did do some surveys with patients that restarted discontinued and

reasons the expect. you might So perhaps are what

side and a Some to patients they give it early they education. more wanted lot of there's mainly because because chance, another effects that decided been stopped

on and There's made. if there's patients early dose sure done, you an making that GI or are headache, things understand physicians upset focused adjustments right. really can that that We’re get be

to so are under oftentimes that get restart a side And help eager that they're reporting through them patients may protocol back and those effects. avoid

that back There I which great didn't new other hey, come factors felt lost been Oxbryta. I have stop job that, been like, reasons and and other like hear. started things my that's hey, but to or patients want job a just to they to I moved; things are people necessarily always report, on So life stopped, would stay, that

so they've to And had a stabilize chance their therapy. and restart now

Kim? the are those main things So back. hear we

Kim Smith-Whitley

increase that for study, And X of quite think that and and Anderson at proportion yes, individuals Alan of higher was hemoglobin rate the impressive. couple a And the the be deciliter may achieved gram in factors there I play. per

effects educating great inclined forward start sample at young people managing side effects those Given still Anderson be going does Oxbryta, a more that center. XX even whatever for size sample that patients, to it's they Dr. with have it's before may may it's single his a sickle proactively. a and and job disease more know discuss a size, nice small side they cell though they We

might increase an so in group. in adherence And be there that

that was have proportion and higher effect thing going may in, a on that his individuals were as stable had well. other The is at small also hydroxyurea a doses of that

Ritu Baral

a Got follow-up very quick it. And housekeeping question.

sickle idea is and of we now? it be Given separate anymore. by MHRA thinking no you a London to about how have were should or post approval the the path in in covered still Brexit, EMA the have there that UK? population I cell importance pursue Is

Ted Love

in be of essentially to continue time and EMA that that is I continue. between long fall a the temporary the Yes, But driven will will don't work, that’s a good plan UK have approval be so the and how question, that timeline that's off Ritu. place know the will that EMA relationship the Yes, the into for window. there will plan.

Operator

is Our Wells Advisors. Yanan proceed. Please with next Zhu Fargo question from

Yanan Zhu

two Good Oxbryta the taking Thanks Hi. on questions. on afternoon. I XXX. and for launch have one my

quarter question in patients For My the talk about more second little And second could probably I of or of patients to is partially least once but the how color And not that over difference the XX% fully provide quarter? of you relationship the high, trajectory on in you there what the the beginning of distributed? launch, are July in to at you think kind on whether more it's as patients launch they terms very new the of bit Oxbryta evenly to although next regard a can are in all mentioned, make distribute quarter. launch? is could distribution course with vaccination think, and those expect we vaccinated in in I the patients a launch is, trend? rate enough the of vaccinated, the

have So gating get do interact a with doctors drug? might And they're whether other impact being Thanks. to with items XXX. vaccination willing their new addition you that I think status to are a in and follow there treated on up

Ted Love

questions a think you. few quite DJ, there for Okay. I

David Johnson

happy those. I'm Yes. Sure. to answer

the QX, although not we're was new -- quarter, there. holidays distribution in those of It is month-to-month here July. pretty pretty even. consistent of reporting of obviously, ones on throughout July the we patients has was course July, the two quarter, regarding holidays. the it the over in you, have remind major of to So one Of quarter, one just the the

ever the And so a volume. with all always July week saw And as holiday. that is around of down week launches Xth dynamic on, same for we I've worked the

little launch. Vaccination you gives on that on and a expectations July. impact color So

rates said, that We're increase does reports the sickle that. will absolutely the into helps patients being in. And confident guidelines They're vaccination still want infectious patients, to on feeling in in right. have yes, population. of vaccinations about that go Delta with concern our all So to around for is saw cell people to to translate be variant we the the going a That going patients, we the think not infected now around CDC on be because cell impact can sickle it particular. super and right it to excited significant in more going a

to closely how about our very are determine it. this monitoring we're feeling patients So

masking new over the major cell in the of read up in A and all today have a to and markets. the XX largest Florida number states. XX the states infections of new our I We requirements number just are in in of seen Those hours right go key together up two third sickle now. three country infections Texas third are country. the make two last

we're monitor understand other half as the a with patients, So first in of and these on have rolling will already a initiatives that patients, also the the think lot closely. vaccinated, physicians, are and will second rolled empowering Delta activating we this said have we very out half that earlier, monitoring our in Like with patients positive going even become this of impact the patients. very but but virus think things are more are I I commercial impact year, better it have and we to CoverMyMeds tactics then have have to closely, out,

Yanan Zhu

you sickle disease patient when hemoglobin designed part, achieve? you. the dosing modification the not hemoglobin completed portion Are the And to sense. Thank of I'm trying Got what XXX, on higher from do to Then healthy the a percent is you for -- the it. completed, of a even strategy in -- achieve that you you modification? a have study, is of since but lot That of sense makes XX% what have the percentage volunteer relationship that you cell now also wondering could than doses? that

Ted Love

that? Kim, do take to you want

Kim Smith-Whitley

Yes.

that first last the first. think actually I So the or -- part part of I'll answer

So good we’ll the at six are with PK/PD cell meeting study healthy out study to share have data. look of volunteer good looking comes will red to later this well hope ASH the some at the parameters that as have cell individuals as you with healthy when we we six volunteer these data year. disease, when of you information the our -- up that at And safety and sickle

really hoping to that dosing. early for more it's these that. too will expect would think But we're say what I studies about provide information that exact we preliminary

Ted Love

a XX% cell that to encouraged I the in us plus day levels has get modification of be thing is sickle these milligrams early looks of only data the can to to XXX the XXX volunteer target the patient. like dose may that add per The in it

that. volunteers of And we said, But ASH. exact supportive at the need that is we early present as data the human that. from obviously, to want So, document data Kim that's to

Operator

Gerberry question Jason Bank with next from America. Please proceed. is Our of

Unidentified Analyst

Hi. Thanks This the on for for [ph] Perry is Jason. taking the question. line

terms context and population? Just terms I if guess about a of should the XX in question And to population in patient in age of Oxbryta think on for of age is approved, be I subgroup X in patient Should this group to how this guess the ramp we this potential we increase faster? sales? adherence expect at

Ted Love

that? tackle to want you DJ,

David Johnson

Sure, to on happy that. comment

any So, that of to as nicely start a to as really of action damage. mechanism yes, the this it's of you downstream in Namely, important prevent would reasons. we expect possible to We want this for ramp lot soon Oxbryta population. think group support patients a

United So really XX patient's important States that old. and XX,XXX patients the years between the in X This are is for health.

So it's the calling on customers. of we've large market. a been And portion these

are them hematologists used and pediatric are of in our in Oxbryta have their XX older. and target that today, So kids list many

safety longer even the So data the approval. have at expanded they they term And and have time efficacy experience. now of

are top probably data children. kids reasons, we'll will a And advocating parents this the ensuring can be game. be adherence. about shows be involved those the their all better of the the get pediatric I The the And than for can our medication. take commercial. that and the So will in younger that, parents we will The population, asking parents think for better parents Kim hematologist, speak seeing ahead in it the the population, of the as for Oxbryta. The on

at highest this expect So we in be adherence would to the level population.

Kim Smith-Whitley

that. I DJ, agree with

Jeff Farrow

up a upped I The XXX. EAP already that set I Perry, well. people. bit is program about We've Jeff, number We that an this to as quite and actually add, XX have is this opportunity thing through blown one would for the think excitement there's of had

as excitement there's bit think a hematology I pediatric patient side the the quite So well as both on of side.

Operator

Please Paul Our Sachs. Goldman with next question is from Choi proceed.

Paul Choi

the on And Good me offer afternoon. quarter congratulations for everyone. Two please. me Hi, let my well. also as

as the regard question identified with you could emerging who and XXX. perhaps assets then comment waiting or [indiscernible] commercial any maybe First, inclacumab dynamic or patients there on trial have guess are on getting is And the for your of I sort differing, for if I Oxbryta? clinical among options, patients, own for such competing therapy be follow-up to just potentially XXX, on may a

Ted Love

might to on today of not. If hope high road. That understood down new be the question, in going would having wait be a tantamount Oxbryta would saying taking be to Paul, on joining your the I ranks available that therapy they I the new to years not drugs. wait blood Sure. I'm and patients pressure

death premature increasing. Your I our damage are education directly is accumulating And only your centered body is risk think around that. and campaigns of

to You transplant. don't going if a for you therapies. you'd thought existing today body road protect your were make want transplant, to lot you're to down on And it get wait the sense on a you while would actually a waiting of

way think after educational strategically on to additional really go our I efforts wise that be So therapies. would a approach not waiting

Paul Choi

sort And the treatment of much. exposure be intend Thank you on available initial of that the follow-up just you here, you be for exposure patients I thinking then that for can sickle you enrolling will cell that, Ted. guess about at thoughts framed potentially results presented relative think these duration help us patients, here for regarding for now you're sort that in maybe are present you And through to and XXX, patients Thanks my duration ASH? might actively question of Okay. very of Voxelotor? how how to

Ted Love

Sure, Paul.

quite we same know lot to free works feel to add and polymerization, through our a Kim, mechanism. So, the that thing nice Oxbryta on is experience with mechanism hemoglobin the the XXX this. about of about But voluminous

So a lot. we can extrapolate think we

thing is compensate like as life, weeks To to giving long is fact would have dose. I for very loading other XXX about The emphasize be opposed likely will in a Oxbryta. we that that a half days, it to that,

there modification, the why very drug would to essentially that So dose the dose. likely would that daily to then very that's replace a the of patients they and be day. a loading each be get metabolize higher dose And quickly will level low

So as we long essentially based hemoglobin occurs rise been in quickly. is was terms think being exposure, the it therapy. maintained, study, of In that HOPE two within And the therapy. Oxbryta, just patient's of weeks on hemoglobin rise as on the on

think anticipate what to think for would look and So I presenting I we with that's we we'll the correct data obviously, But the similar XXX XXX ASH. getting be that. very it But Kim, at that. based expect mechanism. to add please everyone or to would And, on

Kim Smith-Whitley

I agree. question. And first would want No, just Ted. clarify for to Paul's I

I of inclacumab, want a about be be I sure individuals with clear to that in. incentive Oxbryta to think we Oxbryta be that should are would in inclacumab make dose pairing allowed just that participating who on the stable going trials

So I Operator, you hope a be disincentive. are that that wouldn't there? Courtney?

Ted Love

can you Kim, hear us?

Kim Smith-Whitley

you. hear can I

Ted Love

can see me -- Let I if

Steven Immergut

We'll try -- to continue to

Ted Love

just should close. I Maybe

Steven Immergut

Yes.

Ted Love

Okay.

to error. safe I just want free technical of you, please joining It out you have for close. We healthy. And us feel everyone again. thank may Thank a will we We looks a if questions. additional like hope our today. you bit reach and stay any have all to call to

Global Blood Therapeutics (GBT) 4 Aug 212021 Q2 Earnings call transcript